Affini-T’s proprietary platform selects and engineers T cells and combines highly active TCRs with synthetic biology switches to enhance T cell function, durability and tumor infiltration. The company is initially focused on targeting mutant variants of KRAS, a prevalent oncogenic driver mutation in solid tumors. Its platform aims to rewrite the rules of the tumor microenvironment to produce sustained clinical responses in hard-to-treat cancers such as lung, colorectal and pancreatic cancer. Affini-T plans to operationalize its discovery engine and drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. To enable and accelerate growth the company has established a bi-coastal U.S. presence with research labs in Seattle and headquarters and manufacturing infrastructure in Boston. The management team and scientific advisory board include leaders from industry and top research institutions, underscoring the company’s emphasis on translational cellular engineering.

Total raised

$175M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2022